Cargando…
Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation
Anti-tumor immunity can eliminate existing cancer cells and also maintain a constant surveillance against possible relapse. Such an antigen-specific adaptive response begins when tumor-specific T cells become activated. T-cell activation requires two signals on antigen presenting cells (APCs): antig...
Autores principales: | Gujar, Shashi A., Lee, Patrick W. K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3989761/ https://www.ncbi.nlm.nih.gov/pubmed/24782988 http://dx.doi.org/10.3389/fonc.2014.00077 |
Ejemplares similares
-
Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines
por: Holay, Namit, et al.
Publicado: (2017) -
Harnessing Oncolytic Virus-Mediated Anti-Tumor Immunity
por: Schirrmacher, Volker, et al.
Publicado: (2014) -
Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies
por: Gujar, Shashi, et al.
Publicado: (2018) -
Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy
por: Kim, Youra, et al.
Publicado: (2015) -
Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses
por: Zhang, Bin, et al.
Publicado: (2021)